Gelrin C Targets $15 Billion Knee Osteoarthritis Cost Gap with Off-the-Shelf Hydrogel

Knee osteoarthritis (OA) costs the U.S. healthcare system billions of dollars annually, creating a pressing need for treatments that address cartilage damage before it leads to costly joint degeneration. Regentis Biomaterials Ltd. (NYSE American: RGNT) is positioning its product Gelrin C as a practical solution to fill this gap. The company highlights that approximately 470,000 cartilage repair procedures are performed each year in the U.S., representing a multi-billion-dollar market where providers, payers, and patients seek more effective regenerative options.

Gelrin C is a cell-free, off-the-shelf hydrogel designed for a 10-minute procedure that fits within existing surgical workflows. Unlike complex cell-based therapies that require multiple procedures and specialized laboratory processing, Gelrin C offers a streamlined approach. The product targets localized cartilage defects that, if left untreated, can progress to osteoarthritis—a condition that imposes significant clinical and economic challenges.

Articular cartilage has limited ability to regenerate on its own, making untreated lesions vulnerable to deterioration. Advances in regenerative medicine are creating opportunities to address cartilage damage more effectively. Regentis aims to capitalize on this by providing a solution that avoids the logistical hurdles of cell-based treatments.

The company’s press release, disseminated via BioMedWire, emphasizes the economic impact of knee OA. The “$15 billion knee OA spending gap” underscores the potential cost savings from early intervention. Gelrin C is designed to be a smart investment in what the company calls “cartilage economics,” targeting a market where demand for practical regenerative solutions is growing.

Regentis is publicly traded under the ticker RGNT on the NYSE American. The press release was part of a paid marketing engagement with IBN, which will receive $30,000 per quarter for coverage. For more information, the company’s newsroom is available at ibn.fm/RGNT, and full terms of use and disclaimers are posted on the BioMedWire website at https://www.BioMedWire.com/Disclaimer.

BioMedWire, a specialized communications platform focused on biotechnology and life sciences, is part of the Dynamic Brand Portfolio @IBN. It offers services including wire solutions, editorial syndication to over 5,000 outlets, press release enhancement, and social media distribution to millions of followers. The platform aims to help companies reach investors, influencers, and the public.

By offering a cell-free, off-the-shelf hydrogel, Regentis hopes to address the unmet need for practical cartilage repair options. The product’s ability to integrate into existing surgical workflows without additional laboratory processing could make it an attractive alternative to current therapies. As the healthcare system grapples with the rising costs of knee OA, innovations like Gelrin C may play a crucial role in shifting treatment paradigms toward earlier intervention.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Gelrin C Targets $15 Billion Knee Osteoarthritis Cost Gap with Off-the-Shelf Hydrogel.

The post Gelrin C Targets $15 Billion Knee Osteoarthritis Cost Gap with Off-the-Shelf Hydrogel appeared first on citybuzz.